ULTRAGENYX PHARMACEUTICAL INC. (RARE)

Every figure this model derived for RARE, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 4,000,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 292,000,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 606,000,000 AssetsCurrent 2026-06-30
current liabilities 351,000,000 LiabilitiesCurrent 2026-06-30
equity -291,000,000 StockholdersEquity 2026-06-30
ocf -485,000,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 717,212,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 108,505,000 AllocatedShareBasedCompensationExpense 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up RARE on one particular measure came for.

RatioValue
cash operating margin-53.91
current ratio1.73
current ratio reported1.73
deferred revenue growth13.42
dilution pct8.96
fcf margin-68.18
growth cv0.47
operating margin-73.64
owner earnings margin-83.31
revenue growth17.55
revenue growth per share7.89
rule of 40-56.09
sbc pct revenue15.13

What to be careful about

What this model itself distrusts about RARE's figures. Written by the derivation as it ran, not added afterwards.